Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

Makorin-2 Inhibitors

Makorin-2 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the Makorin-2 protein, a member of the zinc finger protein family. Makorin-2 (MKRN2) is known for its role in various cellular processes, including the regulation of RNA metabolism and ubiquitin-mediated protein degradation. It contains multiple zinc finger domains, which allow it to interact with nucleic acids and other proteins, facilitating its function as an E3 ubiquitin ligase. This function is essential in marking certain proteins for degradation by the proteasome, thereby maintaining cellular protein homeostasis. By inhibiting MKRN2, these inhibitors can alter the regulation of these processes, which in turn may influence the stability of key cellular proteins involved in transcription, signaling, and various regulatory mechanisms.

Chemically, Makorin-2 inhibitors are typically characterized by their ability to bind to the zinc finger motifs or to other critical domains necessary for MKRN2's ligase activity. These inhibitors may interact with the active site of MKRN2 or induce conformational changes that reduce its ability to catalyze ubiquitination. Structurally, these compounds often contain reactive groups that form stable interactions with the key residues involved in MKRN2's catalytic function. The study of these inhibitors involves detailed analysis of their binding affinities, structural configurations, and the specific mechanisms through which they disrupt MKRN2's role in ubiquitination pathways. Further exploration into this class of inhibitors has provided insights into their potential to modulate diverse cellular pathways, given the wide-ranging effects of ubiquitin-protein interactions on intracellular signaling and gene expression.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$60.00
$265.00
$1000.00
163
(3)

MG132 might inhibit MKRN2 by blocking the proteasome pathway, which is crucial for protein degradation processes where MKRN2 is involved.

Chloroquine

54-05-7sc-507304
250 mg
$69.00
2
(0)

Chloroquine could affect the lysosomal degradation pathway, indirectly impacting the ubiquitination process where MKRN2 participates.

Autophagy Inhibitor, 3-MA

5142-23-4sc-205596
sc-205596A
50 mg
500 mg
$65.00
$261.00
113
(3)

This compound could inhibit autophagy, indirectly affecting the cellular processes where MKRN2 is involved.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Bortezomib might inhibit the proteasome pathway, affecting the protein degradation where MKRN2 has a role.

Nutlin-3

548472-68-0sc-45061
sc-45061A
sc-45061B
1 mg
5 mg
25 mg
$62.00
$225.00
$779.00
24
(1)

By stabilizing p53, Nutlin-3 could influence the expression of genes involved in the ubiquitin-proteasome pathway, including MKRN2.

Eeyarestatin I

412960-54-4sc-358130B
sc-358130
sc-358130A
sc-358130C
sc-358130D
sc-358130E
5 mg
10 mg
25 mg
50 mg
100 mg
500 mg
$114.00
$203.00
$354.00
$697.00
$1363.00
$5836.00
12
(1)

This compound could inhibit the endoplasmic reticulum-associated degradation, affecting MKRN2 function indirectly.

Ixazomib

1072833-77-2sc-489103
sc-489103A
10 mg
50 mg
$311.00
$719.00
(0)

Ixazomib (MLN2238) might impact the ubiquitination process by inhibiting proteasome activity, affecting MKRN2 function.

Lactacystin

133343-34-7sc-3575
sc-3575A
200 µg
1 mg
$188.00
$575.00
60
(2)

This compound might inhibit proteasome activity, affecting the ubiquitination processes where MKRN2 is involved.

PR 619

2645-32-1sc-476324
sc-476324A
sc-476324B
1 mg
5 mg
25 mg
$77.00
$188.00
$431.00
1
(0)

PR-619 might inhibit ubiquitin-specific proteases, influencing the ubiquitination process where MKRN2 participates.

Carfilzomib

868540-17-4sc-396755
5 mg
$41.00
(0)

Carfilzomib could inhibit the proteasome pathway, affecting the protein degradation processes where MKRN2 is involved.